U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula 2C3H5O3.Mg
Molecular Weight 202.445
Optical Activity ( + / - )
Defined Stereocenters 0 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MAGNESIUM LACTATE

SMILES

[Mg++].CC(O)C([O-])=O.CC(O)C([O-])=O

InChI

InChIKey=OVGXLJDWSLQDRT-UHFFFAOYSA-L
InChI=1S/2C3H6O3.Mg/c2*1-2(4)3(5)6;/h2*2,4H,1H3,(H,5,6);/q;;+2/p-2

HIDE SMILES / InChI
Molecular Formula C3H5O3
Molecular Weight 89.07
Charge -1
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )
Molecular Formula Mg
Molecular Weight 24.305
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Sources: http://www.internationalcrystal.net/optics_11.htm | https://www.ncbi.nlm.nih.gov/pubmed/27792982 | https://www.ncbi.nlm.nih.gov/pubmed/26952467 | https://www.ncbi.nlm.nih.gov/pubmed/27995243https://www.scbt.com/scbt/product/magnesium-nitrate-hexahydrate-13446-18-9 | https://www.ncbi.nlm.nih.gov/pubmed/18964415 | https://www.ncbi.nlm.nih.gov/pubmed/2843308http://www.db-pharma.com/anglais/49.pdfhttp://www.sciencedirect.com/science/article/pii/004484868990080Xhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020309s028lbl.pdfhttps://hazmap.nlm.nih.gov/category-details?table=copytblagents&id=1640DOI: 10.2903/j.efsa.2008.883http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2013.3444/pdfdoi: 10.1081/SCC-120022479https://www.xymogen.com/assets/imageDisplay.ashx?productID=111&attachmentTypeID=1https://www.drugs.com/ppa/magnesium-chloride.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/15480451 | https://www.scbt.com/scbt/product/magnesium-iodide-10377-58-9https://www.drugs.com/dosage/magnesium-lactate.htmlhttp://dx.doi.org/10.1155/2015/498932 | http://iicbe.org/upload/4152C514072.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/351265
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/9873215 | http://discovery.ucl.ac.uk/1336882/1/1336882.pdf

Struvite, a crystalline substance first identified in the 18th century, is composed of magnesium ammonium phosphate. Struvite urinary stones are also known as ‘infection stones’, and account for 15%-20% of all urinary stones. Bacterial urease, usually from a Proteus species, is responsible for the chemical changes in urine which result in struvite formation.

CNS Activity

Originator

Ulex, G.L.
66
Curator's Comment: Ulex, a Swedish geologist, is generally credited with introduction of the term struvite in1845

Approval Year

1921
1467
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Modulator
828
Modulator
828
Modulator
828
Modulator
828
Interacts
323
Protein S100-A8
66
Target ID: P05109
Gene ID: 6279.0
Gene Symbol: S100A8
Target Organism: Homo sapiens (Human)
Binding Agent
1064
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Basic research
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
Preventing
Approved
8429
MAGNESIUM SULFATE

Approved Use

INDICATIONS AND USAGE Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose.

Launch Date

1995
Primary
Approved
8429
MAGNESIUM SULFATE

Approved Use

INDICATIONS AND USAGE Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose.

Launch Date

1995
Diagnostic
Approved
8429
ColPrep Kit

Approved Use

INDICATIONS AND USAGE ColPrep Kit is indicated for cleansing of the colon as a preparation for colonoscopy in adults

Launch Date

2016
Primary
Phase III
656
MAGNESIUM SULFATE

Approved Use

INDICATIONS AND USAGE Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose.

Launch Date

1995
Curative
Approved
8429
MagMin

Approved Use

Magnesium aspartate (MagMin) is indicated for patients with documented hypomagnesaemia.
Curative
Not Provided
504
DELBIASE

Approved Use

Unknown
Primary
Not Provided
504
DELBIASE

Approved Use

Unknown
Primary
Not Provided
504
DELBIASE

Approved Use

Unknown
Curative
Approved
8429
Magnesium Chloride

Approved Use

Magnesium Chloride injection is indicated as an electrolyte replenisher in magnesium deficiencies
Palliative
Phase II
1132
Magnesium Chloride

Approved Use

Unknown
Palliative
Phase III
656
Magnesium Chloride

Approved Use

Unknown
Primary
Approved
8429
EPIMAG

Approved Use

Magnesium citrate is indicated in cases of oxaluria, to prevent recurrence of calcium oxalate kidney stones.
Primary
Approved
8429
EPIMAG

Approved Use

Used to relief of occasional constipation (irregularity).
Curative
Approved
8429
Magnesium Citrate

Approved Use

Magnesium citrate is indicated to supports magnesium nutritional adequacy.
Curative
Approved
8429
Unknown

Approved Use

Magnesium lactate is a naturally occurring mineral that is needed in the body to support the function of the heart, nervous system, and digestive system. Magnesium lactate is used as a mineral supplement to treat magnesium deficiency.
PubMed

PubMed

TitleDatePubMed
Effects of manganese, calcium, magnesium and lithium on the ouabain-induced seizure.
1977
Evidence for separate peptide sequences related to the lipolytic and magnesium-accumulating activities of ACTH. Analogy with adrenergic receptors.
1977 Apr
[Magnesium--an alternative in treatment resistant tachyarrhythmias].
1977 May 30
Serum calcium and magnesium levels in schizophrenia. II. Possible relationship to extrapyramidal symptoms.
1979 Nov
Characterization of the prolactin receptor in human prostate.
1983 Nov
Symptomatic hypercalcaemia precipitated by magnesium therapy.
1985 Jan
Regulation of membrane histamine H1-receptor binding sites by guanine nucleotides, mono- and divalent cations.
1986 Apr
Decreased intracellular free magnesium in erythrocytes of spontaneously hypertensive rats.
1987 Mar 30
Effect of magnesium diet in gentamicin-induced acute renal failure in rats.
1989
[Arrhythmogenic effect of flecainide--treatment with i.v. magnesium].
1989 Sep
Cocaine-induced cerebral vascular damage can be ameliorated by Mg2+ in rat brain.
1990 Feb 5
Modulation of mu, delta and kappa opioid receptors in rat brain by metal ions and histidine.
1990 May
Magnesium inhibits the hypertensive but not the cardiotonic actions of low-dose epinephrine.
1991 Jun
['Cardiac ballet' with and without amiodarone].
1993 Jan 13
Overexpressed protein kinase C-delta and -epsilon subtypes in NIH 3T3 cells exhibit differential subcellular localization and differential regulation of sodium-dependent phosphate uptake.
1994 Feb 18
Cocaine-induced cerebrovasospasm and its possible mechanism of action.
1994 Mar
Differential modulation of alpha 3 beta 2 and alpha 3 beta 4 neuronal nicotinic receptors expressed in Xenopus oocytes by flufenamic acid and niflumic acid.
1995 Mar
Effects of felbamate on muscarinic and metabotropic-glutamate agonist-mediated responses and magnesium-free or 4-aminopyridine-induced epileptiform activity in guinea pig olfactory cortex neurons in vitro.
1996 Jun
The effect of cations on the amidase activity of human tissue kallikrein: 1-linear competitive inhibition by sodium, potassium, calcium and magnesium. 2-linear mixed inhibition by aluminium.
2004 Aug
Major and trace elements in whole blood of phlebotomized patients with porphyria cutanea tarda.
2005
Prevention of succinylcholine-induced fasciculation and myalgia: a meta-analysis of randomized trials.
2005 Oct
Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids.
2005 Oct
Pretreatment with magnesium sulphate is associated with less succinylcholine-induced fasciculation and subsequent tracheal intubation-induced hemodynamic changes than precurarization with vecuronium during rapid sequence induction.
2006
Conformational changes in sarcoplasmic reticulum Ca(2+)-ATPase mutants: effect of mutations either at Ca(2+)-binding site II or at tryptophan 552 in the cytosolic domain.
2006 Apr 25
Further characterization of mammalian ceramide kinase: substrate delivery and (stereo)specificity, tissue distribution, and subcellular localization studies.
2006 Feb
Structure of pyrimidine 5'-nucleotidase type 1. Insight into mechanism of action and inhibition during lead poisoning.
2006 Jul 21
Activation and enzymatic characterization of recombinant human kallikrein 8.
2006 Jun
Evidence for a two-step mechanism involved in the formation of covalent HC x TSG-6 complexes.
2006 Jun 20
Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. II. Pervasive developmental disorder-autism.
2006 Mar
Uncompetitive inhibition of Xenopus laevis aldehyde dehydrogenase 1A1 by divalent cations.
2006 Mar
The expression of genes for transepithelial calcium-transporting proteins in the bovine duodenum.
2006 Mar
Kinetic properties of chimeric class I aldehyde dehydrogenases for retinal isomers.
2006 Oct
The specific, submicromolar-Km ADP-ribose pyrophosphatase purified from human placenta is enzymically indistinguishable from recombinant NUDT9 protein, including a selectivity for Mn2+ as activating cation and increase in Km for ADP-ribose, both elicited by H2O2.
2006 Oct
Divalent-metal-dependent nucleolytic activity of Cu, Zn superoxide dismutase.
2006 Oct
Multivariate analysis of the selected metals in the hair of cerebral palsy patients versus controls.
2006 Summer
Magnesium attenuates isoproterenol-induced acute cardiac dysfunction and beta-adrenergic desensitization.
2007 Mar
Cisplatin-induced hypomagnesemia and cardiac dysrhythmia.
2007 Nov
[The characterization of central neuromediation in rats fed with magnesium-deprived diet before and after magnesium replenishment].
2008 Jul
Inhibition of specific adenylyl cyclase isoforms by lithium and carbamazepine, but not valproate, may be related to their antidepressant effect.
2009 Dec
Differential binding of inorganic particles to MARCO.
2009 Jan
The loop connecting metal-binding domains 3 and 4 of ATP7B is a target of a kinase-mediated phosphorylation.
2009 Jun 23
Involvement of transient receptor potential melastatin-related 7 (TRPM7) channels in cadmium uptake and cytotoxicity in MC3T3-E1 osteoblasts.
2010 Dec 15
Metals affect the structure and activity of human plasminogen activator inhibitor-1. II. Binding affinity and conformational changes.
2011 Feb
Metals affect the structure and activity of human plasminogen activator inhibitor-1. I. Modulation of stability and protease inhibition.
2011 Feb
Mechanically enforced bond dissociation reports synergistic influence of Mn2+ and Mg2+ on the interaction between integrin α7β1 and invasin.
2011 Jul-Aug
NADH fluorescence lifetime analysis of the effect of magnesium ions on ALDH2.
2011 May 30
Warfarin accelerates ectopic mineralization in Abcc6(-/-) mice: clinical relevance to pseudoxanthoma elasticum.
2013 Apr
Ofloxacin induces apoptosis via β1 integrin-EGFR-Rac1-Nox2 pathway in microencapsulated chondrocytes.
2013 Feb 15
Catalytic contribution of threonine 244 in human ALDH2.
2013 Feb 25
Assessment of infantile mineral imbalances in autism spectrum disorders (ASDs).
2013 Nov 11
Patents

Patents

03931199
72
03931205
82
03931302
69
03932463
70
03932472
94
03932479
112
03932483
74
03932524
68
03933824
70
03935253
66
03935271
69
03936470
98
03939091
68
03944589
66
03950406
119
03950427
70
03950525
67
03957788
66
03960906
66
03960907
67
03961066
66
03963724
66
03965143
66
03966648
67
03966773
137
03968231
67
03969368
66
03969384
66
03973022
77
03973030
67
03978121
80
03978129
66
03978130
66
03980795
66
03981917
80
03982001
66
03983164
67
03985729
66
03985817
66
03987009
96
03987091
67
03988205
66
03989724
72
03989749
68
03989841
66
03991106
66
03993773
66
03994961
66
03995054
67
03995056
70
03998834
70
04005147
106
04045433
67
04059595
66
04088772
67
04144333
66
04156786
66
04289816
66
04341767
67
04454357
66
04471070
66
04540815
66
04546195
66
04569941
66
04577011
67
04585885
67
04599341
66
04661260
68
04725688
68
04734420
73
04916235
70
04935430
66
04990319
66
05012019
66
05177240
66
05206229
66
05275950
67
05326548
66
05389640
67
05451591
67
05633237
66
05658908
68
05719148
82
05786353
67
05859290
66
05929067
67
06017928
73
06040331
66
06051712
73
06100275
67
06150526
72
06156767
66
06274737
68
06380218
73
06540905
67
06613708
66
06812355
66
07230017
69
07402595
70
07445915
66
07557213
67
07601736
66
07691842
69
08236943
66
08383835
66
20050130276
66
20060100207
66
20100267970
66
CN106582743
66
DE1110825
66
EP1810974A1
66
EP2259773A1
66
EP2708510A1
66
EP2714042A1
66
US1913539
66
US20060083725
66
US20140076804
66
US2034070
66
US2260004
66
US2877095
66
US3030184
66
US3320048
66
US3377271
66
US3429777
66
US3476510
66
US3760050
66
US3994859
66
US4111835
66
US4535183
66
US4748283
66
US4959222
66
US7182872
66
US7608239
66
US9334166
66
WO2000050046A1
66
WO2005123647A1
68

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Rats: MgF2 dissolved in acetic acid (Mg=0.08 mM, F=0.084 mM) was delivered in the aerosol form https://www.ncbi.nlm.nih.gov/pubmed/20647692
Murine osteomyelitis model: medical pure titanium plates in size of 10 mm × 10 mm × 1 mm were used for the deposition of Magnesium Fluoride (MgF2) film.
Route of Administration: Topical
In Vitro Use Guide
Curator's Comment: Magnesium Chloride
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 20:08:54 GMT 2023
Edited
by admin
on Sat Dec 16 20:08:54 GMT 2023
Record UNII
MT6QI8324A
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MAGNESIUM LACTATE
FCC   INCI   MI   WHO-DD  
INCI  
Official Name English
MAGNESIUM LACTATE, ANHYDROUS
Common Name English
MAGNESIUM DL-LACTATE
Common Name English
MAGNESIUM, BIS(2-HYDROXYPROPANOATO-O1,O2)-, (T-4)-
Common Name English
PROMAGSAN
Brand Name English
MAGNESIUM, BIS(LACTATO)-
Common Name English
MAGNESIUM LACTATE, DL-
Common Name English
MAGNESIUM LACTATE [INCI]
Common Name English
DL-LACTIC ACID MAGNESIUM SALT
Common Name English
MAGNESIUM LACTATE [MI]
Common Name English
MAGNESIUM LACTATE [FCC]
Common Name English
MAGNESIUM DL(-)-2-HYDROXYPROPIONATE
Common Name English
Magnesium lactate [WHO-DD]
Common Name English
E-329
Common Name English
INS NO.329
Common Name English
MAGNESIUM LACTATE ANHYDROUS
Common Name English
ANHYDROUS MAGNESIUM LACTATE, DL-
Common Name English
INS-329
Common Name English
MAGNESIUM LACTATE, (±)-
Systematic Name English
MAGNESIUM, BIS(2-(HYDROXY-.KAPPA.O)PROPANOATO-.KAPPA.O)-, (T-4)-
Common Name English
Classification Tree Code System Code
WHO-VATC QA12CC06
Created by admin on Sat Dec 16 20:08:55 GMT 2023 , Edited by admin on Sat Dec 16 20:08:55 GMT 2023
JECFA EVALUATION INS-329
Created by admin on Sat Dec 16 20:08:55 GMT 2023 , Edited by admin on Sat Dec 16 20:08:55 GMT 2023
WHO-ATC A12CC06
Created by admin on Sat Dec 16 20:08:55 GMT 2023 , Edited by admin on Sat Dec 16 20:08:55 GMT 2023
CODEX ALIMENTARIUS (GSFA) INS-329
Created by admin on Sat Dec 16 20:08:55 GMT 2023 , Edited by admin on Sat Dec 16 20:08:55 GMT 2023
Code System Code Type Description
DRUG BANK
DB14515
Created by admin on Sat Dec 16 20:08:55 GMT 2023 , Edited by admin on Sat Dec 16 20:08:55 GMT 2023
PRIMARY
PUBCHEM
5319192
Created by admin on Sat Dec 16 20:08:55 GMT 2023 , Edited by admin on Sat Dec 16 20:08:55 GMT 2023
PRIMARY
SMS_ID
100000089068
Created by admin on Sat Dec 16 20:08:55 GMT 2023 , Edited by admin on Sat Dec 16 20:08:55 GMT 2023
PRIMARY
DRUG CENTRAL
4592
Created by admin on Sat Dec 16 20:08:55 GMT 2023 , Edited by admin on Sat Dec 16 20:08:55 GMT 2023
PRIMARY
GRAS Notification (GRN No.)
570
Created by admin on Sat Dec 16 20:08:55 GMT 2023 , Edited by admin on Sat Dec 16 20:08:55 GMT 2023
PRIMARY
RXCUI
214688
Created by admin on Sat Dec 16 20:08:55 GMT 2023 , Edited by admin on Sat Dec 16 20:08:55 GMT 2023
PRIMARY RxNorm
WIKIPEDIA
Magnesium lactate
Created by admin on Sat Dec 16 20:08:55 GMT 2023 , Edited by admin on Sat Dec 16 20:08:55 GMT 2023
PRIMARY
EVMPD
SUB14431MIG
Created by admin on Sat Dec 16 20:08:55 GMT 2023 , Edited by admin on Sat Dec 16 20:08:55 GMT 2023
PRIMARY
MERCK INDEX
m7006
Created by admin on Sat Dec 16 20:08:55 GMT 2023 , Edited by admin on Sat Dec 16 20:08:55 GMT 2023
PRIMARY Merck Index
ECHA (EC/EINECS)
242-671-4
Created by admin on Sat Dec 16 20:08:55 GMT 2023 , Edited by admin on Sat Dec 16 20:08:55 GMT 2023
PRIMARY
CAS
18917-93-6
Created by admin on Sat Dec 16 20:08:55 GMT 2023 , Edited by admin on Sat Dec 16 20:08:55 GMT 2023
PRIMARY
EPA CompTox
DTXSID20872620
Created by admin on Sat Dec 16 20:08:55 GMT 2023 , Edited by admin on Sat Dec 16 20:08:55 GMT 2023
PRIMARY
FDA UNII
MT6QI8324A
Created by admin on Sat Dec 16 20:08:55 GMT 2023 , Edited by admin on Sat Dec 16 20:08:55 GMT 2023
PRIMARY
ChEMBL
CHEMBL3707281
Created by admin on Sat Dec 16 20:08:55 GMT 2023 , Edited by admin on Sat Dec 16 20:08:55 GMT 2023
PRIMARY
DAILYMED
MT6QI8324A
Created by admin on Sat Dec 16 20:08:55 GMT 2023 , Edited by admin on Sat Dec 16 20:08:55 GMT 2023
PRIMARY
Related Record Type Details
Structure of MAGNESIUM LACTATE TRIHYDRATE
SOLVATE->ANHYDROUS
Structure of LACTIC ACID, DL-
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of MAGNESIUM CATION
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966